ストックスクリーナーアプリを入手
3.00
3.85%
-0.12
アフターアワーズ：
3.03
0.03
+1.00%
前日終値:
$3.12
開ける：
$3.2
24時間の取引高:
53,107
Relative Volume:
0.12
時価総額：
$3.62M
収益：
$4.96M
当期純損益:
$-6.82M
株価収益率:
-0.0459
EPS:
-65.4
ネットキャッシュフロー:
$-6.64M
1週間 パフォーマンス:
-5.06%
1か月 パフォーマンス:
-28.91%
6か月 パフォーマンス:
-62.28%
1年 パフォーマンス:
-63.12%
1日の値動き範囲:
$2.98
$3.20
1週間の範囲:
$2.98
$3.48
52週間の値動き範囲:
$2.414
$15.70
Inmed Pharmaceuticals Inc Stock (INM) Company Profile
名前
Inmed Pharmaceuticals Inc
セクター
電話
(604) 669-7207
住所
1445-885 WEST GEORGIA ST., VANCOUVER
INM を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
INM
Inmed Pharmaceuticals Inc
|
3.00 | 3.62M | 4.96M | -6.82M | -6.64M | -65.40 |
|
ZTS
Zoetis Inc
|
165.31 | 74.02B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.15 | 45.90B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.08 | 44.64B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.78 | 19.23B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
128.57 | 13.67B | 612.78M | -86.37M | -62.91M | -0.87 |
Inmed Pharmaceuticals Inc (INM) 最新ニュース
InMed Pharmaceuticals Struggles with Losses Amid Revenue Decline - MSN
InMed Pharmaceuticals Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update - Defense World
InMed Pharmaceuticals Board Reshuffle After Director Resignation - TipRanks
InMed Pharmaceuticals Reports Q2 2025 Financial Results - TipRanks
InMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update - Yahoo Finance
InMed Pharmaceuticals Inc. (INM) reports earnings - Quartz
InMed Pharmaceuticals Inc. SEC 10-Q Report - TradingView
InMed Advances INM-089 for Dry AMD Treatment with New Intravitreal Formulation - TipRanks
Inmed selects IVT formulation of INM-089 for dry AMD - BioWorld Online
InMed advances AMD treatment with promising IVT drug formulation - MSN
Revolutionary Eye Drug INM-089 Achieves 10X Therapeutic Levels in Macular Degeneration Treatment - StockTitan
Inmed Pharmaceuticals Inc (INM-Q) QuotePress Release - The Globe and Mail
InMed Pharmaceuticals (NASDAQ: INM) Secures International Patent for Novel Compounds - Defense World
InMed Pharmaceuticals Secures Key Patent for Cannabinoid Analogs - TipRanks
InMed Pharmaceuticals secures international patent - Investing.com India
InMed Pharmaceuticals Announces Granting of Patent for Novel Compounds - Newsfile
InMed Secures Breakthrough 20-Year Patent in Mexico for Novel Cannabinoid Compounds - StockTitan
Nano-Cap InMed Ignites Retail Frenzy As Stock Soars After Alzheimer's Drug Trial Shows Promise - Asianet Newsable
InMed Pharmaceuticals (NASDAQ: INM) Announces Positive Results from INM-901 Alzheimer’s Disease Study - Defense World
InMed Hails Alzheimer's Study, Stocks Shoot Higher - Baystreet.ca
InMed announces ‘positive’ results from in vivo preclinical Alzheimer’s study - TipRanks
InMed’s INM-901 Shows Promising Results in Preclinical Alzheimer’s Study - TipRanks
InMed's INM-901 Demonstrates Statistically Significant Reduction in Neuroinflammation in a Long-Term Preclinical Alzheimer's Disease Study - Newsfile
InMed's Alzheimer's Drug Shows Breakthrough Results in Reducing Brain Inflammation - StockTitan
SABBY MANAGEMENT, LLC Acquires Shares in InMed Pharmaceuticals I - GuruFocus.com
InMed Pharmaceuticals Inc. Holds 2024 Annual General Meeting – Elects Directors and Appoints Auditor - Defense World
InMed Pharmaceuticals Director Faces Resignation After Shareholder Vote at Annual Meeting - StockTitan
InMed Announces Results of 2024 Annual General Meeting - Newsfile
InMed Pharmaceuticals Inc. announced that it expects to receive CAD 10 million in funding - Marketscreener.com
InMed Enters Into Standby Equity Purchase Agreement - Newsfile
Head-To-Head Review: InMed Pharmaceuticals (NASDAQ:INM) & Rocket Pharmaceuticals (NASDAQ:RCKT) - Defense World
InMed Pharmaceuticals Secures $10M Equity Purchase Agreement in Strategic Financing Move - StockTitan
InMed Pharmaceuticals (TSE:IN) Trading Down 1.6% – Time to Sell? - Defense World
InMed Pharmaceuticals (FRA:MWG) Altman Z-Score : -14.86 (As of Dec. 05, 2024) - GuruFocus.com
InMed Pharmaceuticals (FRA:MWG) Altman Z-Score : -14.90 (As of Dec. 03, 2024) - GuruFocus.com
InMed Pharmaceuticals (FRA:MWG) Inventories, Finished Goods : €0.84 Mil (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (FRA:MWG) Shares Outstanding (EOP) : 0.67 Mil (As of Sep. 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) Total Liabilities : $2.07 Mil (As of Sep. 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) Debt-to-Equity : 0.13 (As of Sep. 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) Dividend Yield % : 0.00% (As of Nov. 26, 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) Dividend Payout Ratio : 0.00 (As of Sep. 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) EBITDA : $-6.66 Mil (TTM As of Sep. 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) 3-Year Dividend Growth Rate : 0.00% (As of Sep. 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) Cash, Cash Equivalents, Marketa - GuruFocus.com
INM (InMed Pharmaceuticals) Growth Rank : 0 (As of Nov. 26, 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) Machinery, Furniture, Equipment : $0.04 Mil (As of Sep. 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) 3-Year EPS without NRI Growth R - GuruFocus.com
INM (InMed Pharmaceuticals) Total Inventories : $1.22 Mil (As of Sep. 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) Net Income : $-6.82 Mil (TTM As of Sep. 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) Inventory Turnover : 0.63 (As of Sep. 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) Revenue per Share : $49.03 (TTM As of Sep. 2024) - GuruFocus.com
Inmed Pharmaceuticals Inc (INM) 財務データ
収益
当期純利益
現金流量
EPS
0.92%
1.31%
大文字化:
|
ボリューム (24 時間):